biopharm, All this being said also means that at this point it is Blackrock believe the leverage will be in the share price and NOT in hi-jacking on the side otherwise they wouldn't be filling up such huge positions.
Well huge in PPHM terms because owning about 7% of PPHM isn't a big deal for Blackrock money wise. But it is a large (the largest after Ken. Dart) in PPHM, that is listed.
You think this group controls the entire hospital network of New York state re what clinical trials might be run by a given hospital?:
"So this all started by easily seeing "no clinical trials" offered in NY for Bavituximab+Docetaxel in Sunrise Phase III and why?? ... connecting those BlackRock dots to NYU hospital networks and the resistance they naturally have against Peregrine/PS Targeting to advance and Lori/Laurence Fink... and now seeing Lori Fink is also Chair of Perlmutter Cancer Center Advisory Board.... so we shall see where this path leads....."
Market Data 
Markets 
AI
